What is PSA?
PSA stands for prostate-specific antigen. It is produced by prostate cells and a small amount normally enters the bloodstream. PSA is useful because prostate cancer can increase it—but PSA is not cancer-specific. A high value therefore tells us that the prostate deserves assessment; it does not tell us the diagnosis by itself.
Why can PSA be raised?
Is there one “normal” PSA value?
No single cut-off separates cancer from non-cancer. PSA behaves as a continuous risk marker: in general, the higher the PSA, the greater the probability that clinically important prostate cancer may be present, but age, prostate size, medications, examination findings, previous PSA values and other risk factors all matter.
This is why a PSA of 5 ng/mL may mean something quite different in two different men. A large benign prostate may explain much of the value in one patient, while the same PSA with a small prostate and a suspicious MRI may deserve more concern in another.
Should a newly raised PSA be repeated?
Often, yes. Current European and American guidance supports confirming a newly elevated PSA before moving directly to secondary biomarkers, MRI or biopsy, particularly when the rise is modest and there is no urgent clinical concern.
Empirical antibiotics should not be used simply to “treat the PSA” in an otherwise asymptomatic patient. If infection is genuinely suspected, it should be assessed and treated on its own merits.
What else matters besides the PSA number?
- PSA trend: whether the value is stable, rising gradually or has changed abruptly.
- Prostate volume: a larger benign prostate may produce more PSA.
- PSA density: PSA divided by prostate volume can help place the value in context.
- Digital rectal examination: a suspicious examination changes the level of concern.
- Family history and inherited risk: some men have a higher baseline risk of prostate cancer.
- Age and general health: the value of further diagnosis depends partly on whether finding a cancer would meaningfully change care.
- Medication: medicines such as finasteride or dutasteride can substantially reduce PSA and must be accounted for when interpreting the result.
Where does prostate MRI fit?
Multiparametric MRI has become an important part of evaluating many men with persistently abnormal PSA. It can identify areas that look suspicious for clinically significant cancer and can help decide whether biopsy is needed and where biopsy samples should be targeted.
MRI does not make biopsy unnecessary in every patient. A reassuring MRI lowers risk, but the final decision also depends on PSA density, examination, family history, previous biopsy history and the overall clinical picture.
What is PSA density?
PSA density is calculated by dividing the PSA value by the prostate volume. It helps answer a useful question: is the PSA broadly proportionate to the amount of prostate tissue present?
A higher PSA density increases concern for clinically significant cancer, while a low PSA density can be reassuring, especially when combined with a non-suspicious MRI. It should be interpreted as part of a risk assessment rather than as an isolated pass/fail number.
Does a raised PSA automatically mean biopsy?
No. The modern pathway is increasingly risk-based. Depending on the situation, a biopsy decision may incorporate repeat PSA, MRI, PSA density, age, examination, family history, prior biopsy history and, in selected patients, additional blood or urine biomarkers.
If biopsy is recommended, the aim is not simply to find any prostate cancer. The more important goal is to identify clinically significant cancer that could affect health or treatment decisions.
What if MRI shows a suspicious area?
A suspicious MRI does not itself prove cancer, but it increases the rationale for biopsy. Targeted biopsy of the MRI lesion is commonly combined with an appropriate systematic sampling strategy depending on the clinical setting and current guideline approach.
What if the MRI is normal?
A normal MRI is reassuring but not an absolute guarantee that significant cancer is absent. In some men, a normal MRI plus low PSA density and otherwise low clinical risk may support surveillance rather than immediate biopsy. In others—particularly when the PSA density, examination or risk profile remains concerning—biopsy may still be discussed.
What should you bring to a PSA consultation?
- All previous PSA results, not just the latest report
- Any prostate ultrasound or MRI report
- Details of prostate or urinary medications
- History of recent urinary infection, retention, catheterisation or cystoscopy
- Family history of prostate cancer, especially at a younger age
- Previous prostate biopsy reports, if any
- Relevant urinary symptoms and how much they affect daily life
Does a raised PSA mean prostate cancer?
No. PSA can be elevated by benign enlargement, inflammation, infection, urinary retention and other non-cancer causes. Cancer is one possibility, so a persistent elevation should be interpreted properly rather than assumed to be benign or malignant.
Can an enlarged prostate raise PSA?
Yes. Larger benign prostates often produce more PSA. This is one reason prostate volume and PSA density can be useful during assessment.
Should I repeat my PSA before MRI or biopsy?
Often yes, especially when the elevation is new or modest. The timing depends on the clinical situation and whether there has been infection, retention or recent urinary tract instrumentation.
Can MRI rule out prostate cancer?
No test rules it out completely. MRI can substantially improve risk assessment, but PSA density, examination, family history and other clinical factors still matter.
Does a high PSA always require biopsy?
No. Biopsy decisions are increasingly based on the overall risk of clinically significant cancer rather than PSA alone.
Clinical references
This page is informed by the European Association of Urology Guidelines on Prostate Cancer: Diagnostic Evaluation and the AUA/SUO Early Detection of Prostate Cancer Guideline. Guidelines support clinical decision-making but do not replace individual assessment.